NCT06471361View on ClinicalTrials.gov

A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

PHASE3CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 27, 2024

Primary Completion Date

January 28, 2025

Study Completion Date

February 3, 2025

Conditions
Generalized Myasthenia Gravis
Interventions
DRUG

Zilucoplan

Zilucoplan will be self-administered subcutaneously by study participants at pre-specified time points.

Trial Locations (11)

27599

Dv0013 50556, Chapel Hill

33612

Dv0013 50634, Tampa

43221

Dv0013 50635, Columbus

53228

Dv0013 50636, Greenfield

64212

Dv0013 50648, Columbia

78759

Dv0013 50555, Austin

06511

Dv0013 50628, New Haven

Unknown

Dv0013 40609, Katowice

Dv0013 40759, Krakow

Dv0013 40605, Poznan

Dv0013 40760, Oxford

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY

NCT06471361 - A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis | Biotech Hunter | Biotech Hunter